Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics Inc., a biopharmaceutical company specializing in infectious diseases, has reported unanimous shareholder approval for all resolutions at its annual and special meeting. Key outcomes include the re-election of directors, the re-appointment of PricewaterhouseCoopers as independent auditor, and approval for the company’s transition under the Business Corporations Act (Ontario). These decisions mark a strong mandate for the company’s direction and governance.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
